Podcast appearances and mentions of stacey clardy

In the final episode of this three-part series, Dr. Stacey Clardy and Max Goldman talk about telehealth.  Stay updated with everything related to Neurology on the Hill. Show transcript:  Dr. Stacey Clardy: Hi, this is Stacey Clardy, and today we're wrapping up our three-part series covering the Top Advocacy Issues for Neurology on the Hill 2026 in Washington, DC. This is the event where many neurologists fly in from all over the country to meet with our elected representatives to discuss the issues of the most importance to our patients, and to allow us to continue to take good quality care of our neurology patients. We have again back with us, Max Goldman. He's the Director of Congressional Affairs from the AAN Legislative Team. Max, we covered Medicare, we covered neuroscience research in the Brain Initiative. The third and final issue is telehealth. What do we need to accomplish on telehealth in Washington, DC this year? Max Goldman: The telehealth flexibilities provided with the COVID-19 public health emergency have been so important to providing neurological care to patients across the country. However, what we saw during the government shutdown at the end of 2025 was a lapse in those flexibilities, which caused a huge amount of panic, of uncertainty for both our members, the AAN, who are providing care, and patients who relied on care through telehealth from their neurologist. That can't happen again. These flexibilities have been extended short-term basis for one year, two year, a couple of months, and what we need now is a permanent extension of these flexibilities so they can't lapse again, and our patients know they can access the care they need. What we're doing at Neurology on the Hill is going to ask our members of Congress to co-sponsor the Connect for Health Act. This bill would permanently extend telehealth flexibilities, including a full extension of protection of audio-only visits, which is important for folks in areas without great broadband or access to internet. This would just be a really good bill. It's got a lot of momentum this year, and we're hopeful that this will finally make telehealth a permanent part of neurological care going forward. Dr. Stacey Clardy: So important. I certainly know out here in Utah where we cover several rural states, this has really been a lifeline to our patients. To learn more about this issue and the other issues being discussed at Neurology on the Hill, you can go to AAN.com and click on advocacy. Thanks for listening, and thank you Max, for representing us in DC.   

In the second installment of this three-part series, Dr. Stacey Clardy and Max Goldman discuss neuroscience research and the BRAIN Initiative.  Stay updated with everything related to Neurology on the Hill. Show transcript:  Dr. Stacey Clardy:  Hi, this is Stacey Clardy. We are going to continue with our three-part series today about the top advocacy issues covered at Neurology on the Hill 2026 in Washington, DC. Again, as many of you know, this is the AAN's annual advocacy fly-in event. Neurologists come from all over the US to Washington and meet with elected representatives to discuss issues of high importance to allow us to continue providing high-quality care to patients in the US with neurological diseases. In the first minute, we discuss the topic of Medicare, and I have with me again, Max Goldman, director of Congressional Affairs from the AAN legislative team, to talk to us about issue number two, which is neuroscience research, and specifically the BRAIN Initiative. Max, what are we going to discuss about neuroscience research? What do we need to happen in order to continue doing high-quality research? Max Goldman: So, this one is so important, and there's this wonderful program at the NIH called The BRAIN Initiative. This was founded in 2013, really reinforced in 2016 with the 21st Century Cures Act. It's just funding for basic research into how the brain works, right? And the idea behind this is that if we can understand how the brain works, we can find the next generation of treatment or cures for neurological conditions, psychiatric conditions, and issues that go through the brain. This year, we are in a precarious position. Mandatory funding for this program is expiring, and so we're going to lose a lot of money and a lot of opportunities to provide more grants to people to figure out how the brain works. So, what we are doing on Neurology on the Hill is we're asking members of Congress to support $468 million in funding in fiscal year 2027 for the BRAIN Initiative, so we can keep up the good work and keep working towards the next generation of treatments and cures for neurological conditions. Dr. Stacey Clardy: So important. Thank you, Max. To learn more about this issue and the other two issues, you can go to AAN.com. Click on advocacy. And stick with us for the third Neurology Minute, where we will get to the final issue to be discussed, telehealth. 

In the first part of this three-part series, Dr. Stacey Clardy and Max Goldman discuss the state of Medicare in 2026. Stay updated with everything related to Neurology on the Hill. Show transcript: Dr. Stacey Clardy: Hi, this is Stacey Clardy. Today, we're going to start the first of a three-part series about the top advocacy issues at Neurology on the Hill 2026 in Washington, DC. As many of you know, this is the AAN's Annual Advocacy fly-in event in the US, where neurologists come to Washington and meet with our elected representatives to discuss the issues that are important for all of us in the US to continue providing high-quality care to patients with neurological diseases. Every year in preparation for this event, the AAN selects a few issues to focus on with our lawmakers, and we're going to cover those in a three-minute series. We have Max Goldman, the Director of Congressional Affairs from the AAN Legislative Team, to give us the details. Max, the first topic that will be covered at Neurology on the Hill this year is Medicare. What do we need to know about the state of Medicare in 2026? Max Goldman: Thank you so much for having me. As many of you know, the way the Medicare physician fee schedule works and the way that you all are reimbursed for the care you provide patients across the country has been broken for several years. We have this cycle of indiscriminate cuts that keeps happening, where the CMS will present a fee schedule, it'll have a cut for you all, then we have to go to Congress to beg for them to fix the cut. This year, we are talking to Congress about a structural reform that they can make, so we don't have to do that anymore, and the reimbursement that you all receive is commensurate with cost of actually providing care. This year we're going to ask for two things. We're going to ask for them to adjust the triggers to the budget neutrality requirement in the fee schedule, meaning that CMS can make some more changes to the fee schedule without requiring cuts to everyone's reimbursement, and we're going to request that they provide a permanent inflationary adjustment to physician reimbursement so that the reimbursement you get is in track with the cost of providing care in any given year. Dr. Stacey Clardy: Thanks for that summary. Here's hoping to get some traction on that. To learn more about this issue, you can go to aan.com and click on advocacy. And in the upcoming two minutes, we are going to discuss the other issues being brought to Congress at Neurology on the Hill. Thank you for listening to today's Neurology Minute. 

In the second episode of this two-part series, Dr. Stacey Clardy and Dr. John Ney discuss why deaths from neurologic conditions are decreasing, but disability is rising, and what this shift means for future care.  Show citation:  Ney JP, Steinmetz JD, Anderson-Benge E, et al. US Burden of Disorders Affecting the Nervous System: From the Global Burden of Disease 2021 Study. JAMA Neurol. 2026;83(1):20-34. doi:10.1001/jamaneurol.2025.4470  Show transcript:  Dr. Stacey Clardy: Hi, this is Stacey Clardy from the Salt Lake City VA and the University of Utah. I've been talking with John Ney from Yale about why neurologic disease now represents the top source of disability in the United States. John, for the minute, deaths from neurologic conditions are declining overall, right? But disability is increasing. So what does that shift mean for how we, the health system, should be planning for neurologic care? Dr. John Ney: I would say overall, both deaths and disability are increasing as a function of greater life expectancy in the population and, then relative to 1990, a greater increase in population of 50 million individuals came into the US either through birth or immigration during that time. So both of those are going up when we actually look by adjusting for age and per 100,000 individuals, both are actually going down, but not at a rate that we would like. So I think there's a lot more work to do. Dr. Stacey Clardy: Understood. Amongst our growing population, neurologic disability is still the leading cause and not less of a problem. For more details, we really get into the specifics and break this down by states even, take a listen to the full-length neurology podcast. And also check out the paper, it is packed with all of the data. It's in JAMA Neurology. It's titled: US Burden of Disorders Affecting the Nervous System from the Global Burden of Disease 2021 study.

In part one of this two-part series, Dr. Stacey Clardy and Dr. John Ney break down the key message neurologists need to understand from this update and offer guidance on how to clearly convey it to patients. Show citation:  Ney JP, Steinmetz JD, Anderson-Benge E, et al. US Burden of Disorders Affecting the Nervous System: From the Global Burden of Disease 2021 Study. JAMA Neurol. 2026;83(1):20-34. doi:10.1001/jamaneurol.2025.4470  Show transcript:  Dr. Stacey Clardy: Hi, this is Stacey Clardy from the Salt Lake City VA in the University of Utah. I've been talking with John Ney from Yale about a global burden of disease analysis showing that disorders affecting nervous system health are the leading cause of disability in the United States. This is probably not too surprising to any neurologist, but very important that they rigorously went through to prove what we experience in clinics. So John, for the Minute, when neurologists do hear it though, when they hear it out loud that more than half of the US population is affected by neurologic conditions, we're still a little skeptical. That's one in two, right? What's the single most important thing we need to understand about how that number was calculated and how to communicate it to our patients and our communities? Dr. John Ney: It's not just the sum of all conditions added up and then translated into the entire population. It's really looking at unique persons with a condition affecting the nervous system. And certainly our top two are tension type headache and migraine, but then we also get into diabetic neuropathy with 17 million individuals, stroke and Alzheimer's with six million and five million respectively. So individuals, unique persons may have more than one of these conditions, but 180 million or more persons in the United States or 54% of the population actually has at least one of these conditions. Dr. Stacey Clardy: So important that we understand this, these numbers. This matters to our patients when we're explaining it to them. Sometimes they feel alone, but this really also matters when we're talking about what we need for our patients as neurologists, more research, more resources. If you want to learn more, listen to the full-length podcast. We get into the discussion, even breaking it down by states and conditions, and a bit more of the health economics and what informs these numbers. And also check out the paper in JAMA Neurology. It's titled US Burden of Disorders Affecting the Nervous System from the Global Burden of Disease 2021 Study.

Dr. Stacey Clardy talks with Dr. John Ney about the prevalence, disability burden, and societal impact of neurologic disorders in the U.S.  Read the related article in JAMA.  Disclosures can be found at Neurology.org. 

In the second installment of this two-part series, Drs. Stacey Clardy, Ayush Gupta, and Kuntal Sen discuss the most practical testing approach to minimize both under‑ and over‑testing for these disorders. Show citation: Gupta A, Sahjwani D, Kahn I, Gombolay GY, Sen K. Monogenic Mimics of Neuroinflammatory Phenotypes in Children and Young Adults: An Evolving Landscape. Neurol Genet. 2025;11(6):e200326. Published 2025 Nov 25. doi:10.1212/NXG.0000000000200326 Show transcript:  Dr. Stacey Clardy: Hi, this is Stacey Clardy from the Salt Lake City VA in the University of Utah. For a two-part podcast series this week, I've been speaking with Ayush Gupta, from the University of Nebraska Medical Center, and Kuntal Sen, from Children's National Hospital in Washington, DC about monogenic disorders that mimic neuroinflammatory disease. There are a lot of them, and they are no doubt sitting in our clinics waiting to be recognized. Ayush, for the minute, once a neurologist starts suspecting one of these disorders, what's the most practical testing strategy to avoid both under and over-testing for these disorders? Dr. Ayush Gupta: I think the most practical strategy is to write down all the phenotypic symptoms that you think could be related, put that exact information into a genetic testing panel that will be suitable. Or, if possible, try to do a broader genetic testing such as whole genome sequencing, and make yourself equipped to be able to analyze the results that you get from the testing. Dr. Stacey Clardy: I hear you saying, at least when you're thinking about this, be a bit of a lumper. As we covered in the podcast, if we are going to pursue that genetic testing, it is absolutely critical that we share that list with the interpreting geneticist because that determines how they score variants and how they rate them as related or not. Please take a listen to that two-part podcast series, where we get into all these details. I walked away with a great framework on how to do better in terms of picking these disorders out. Again, the paper that accompanies the two-part podcast series is in Neurology Genetics. It's a comprehensive review and called Monogenic Mimics of Neuroinflammatory Phenotypes in Children and Young Adults in Evolving Landscape. Thank you, Ayush. Dr. Ayush Gupta: Thank you so much.

In the second installment of this two-part series, Drs. Stacey Clardy, Ayush Gupta, and Kuntal Sen discuss the most practical testing approach to minimize both under‑ and over‑testing for these disorders. Show citation: Gupta A, Sahjwani D, Kahn I, Gombolay GY, Sen K. Monogenic Mimics of Neuroinflammatory Phenotypes in Children and Young Adults: An Evolving Landscape. Neurol Genet. 2025;11(6):e200326. Published 2025 Nov 25. doi:10.1212/NXG.0000000000200326 Show transcript:  Dr. Stacey Clardy: Hi, this is Stacey Clardy from the Salt Lake City VA in the University of Utah. For a two-part podcast series this week, I've been speaking with Ayush Gupta, from the University of Nebraska Medical Center, and Kuntal Sen, from Children's National Hospital in Washington, DC about monogenic disorders that mimic neuroinflammatory disease. There are a lot of them, and they are no doubt sitting in our clinics waiting to be recognized. Ayush, for the minute, once a neurologist starts suspecting one of these disorders, what's the most practical testing strategy to avoid both under and over-testing for these disorders? Dr. Ayush Gupta: I think the most practical strategy is to write down all the phenotypic symptoms that you think could be related, put that exact information into a genetic testing panel that will be suitable. Or, if possible, try to do a broader genetic testing such as whole genome sequencing, and make yourself equipped to be able to analyze the results that you get from the testing. Dr. Stacey Clardy: I hear you saying, at least when you're thinking about this, be a bit of a lumper. As we covered in the podcast, if we are going to pursue that genetic testing, it is absolutely critical that we share that list with the interpreting geneticist because that determines how they score variants and how they rate them as related or not. Please take a listen to that two-part podcast series, where we get into all these details. I walked away with a great framework on how to do better in terms of picking these disorders out. Again, the paper that accompanies the two-part podcast series is in Neurology Genetics. It's a comprehensive review and called Monogenic Mimics of Neuroinflammatory Phenotypes in Children and Young Adults in Evolving Landscape. Thank you, Ayush. Dr. Ayush Gupta: Thank you so much.

In the second installment of this two-part series, Dr. Stacey Clardy talks with Drs. Ayush Gupta and Kuntal Sen about the spinal cord and optic neuritis, while outlining practical approaches to genetic testing and emphasizing the importance of collaboration with genetic counselors and neurogeneticists.  Read the related article in Neurology® Genetics.  Disclosures can be found at Neurology.org. 

In part one of this two-part series, Dr. Stacey Clardy and Drs. Ayush Gupta and Kuntal Sen discuss the key clinical features that should shift suspicion from autoimmune encephalitis or demyelinating disease to monogenic mimics.  Show citation: Gupta A, Sahjwani D, Kahn I, Gombolay GY, Sen K. Monogenic Mimics of Neuroinflammatory Phenotypes in Children and Young Adults: An Evolving Landscape. Neurol Genet. 2025;11(6):e200326. Published 2025 Nov 25. doi:10.1212/NXG.0000000000200326 Show transcript:  Dr. Stacey Clardy: Hi, this is Stacey Clardy from the Salt Lake City VA in the University of Utah. For a two-part podcast series, I've been speaking with Ayush Gupta from the University of Nebraska Medical Center and Kuntal Sen from Children's National Hospital in Washington DC about the monogenic disorders that mimic neuroinflammatory disease that are lurking in all of our clinics just waiting to be diagnosed. Ayush, for the minute, when you're seeing a patient with a presumed autoimmune encephalitis or demyelinating disease, what single cluster of features should instead most strongly push us to think of monogenic mimics at the top of our differential? Dr. Ayush Gupta: So when you are seeing a patient with presumed autoimmune encephalitis or a demyelinating disorder, cluster of features such as earlier onset in terms of age, developmental delays, CSF or imaging finding that's non-concordant with the diagnosis such as a non-inflammatory CSF, a symmetric white matter or deep gray matter involvement and relentless progression despite immunotherapy, these are the red flags where you should stop, seriously consider the possibility of a monogenic disorder and reach out to help from colleagues. Dr. Stacey Clardy: That's a great list, and we get into far more detail in the two-part podcast series. So please listen to both of those and take a read of the neurology genetics review titled Monogenic Mimics of Neuroinflammatory Phenotypes in Children and Young Adults: An Evolving Landscape.

In part one of this two-part series, Dr. Stacey Clardy talks with Drs. Ayush Gupta and Kuntal Sen about the phenotypes commonly seen in CNS inflammatory and demyelinating diseases, and discuss genetic conditions in patients who do not precisely meet classic diagnostic criteria. Read the related article in Neurology® Genetics.  Disclosures can be found at Neurology.org. 

Start the new year with the January 2026 Recall, featuring five episodes focused on the topic of AI in neurology. The episode begins with Dr. Stacey Clardy talking with Stephen Marche about the evolving topic of natural language processing and its impact on neurology and everyday life. The episode leads into a conversation with Drs. Halley Alexander and Sándor Beniczky discussing the use of AI to accurately interpret routine clinical EEG. The conversation continues with Drs. Trey Bateman and David T. Jones discussing the use of FDG-PET imaging and machine learning to improve diagnostic accuracy. The episode transitions into a discussion between Dr. Andy Southerland and Dr. Adam Rodman regarding the implications of LLMs in clinical reasoning and diagnostics. This month's Recall concludes with Dr. Stacey Clardy reflecting on how AI is shaping multiple aspects of life, including podcasts. Podcast links: What Natural Language Processing Could Mean for Careers in Neurology and Publications Artificial Intelligence Interpretation of EEG FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making Superhuman Performance of a LLM on the Reasoning Tasks of a Physician Podcasting in the Age of AI Article links:  The College Essay Is Dead Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence An FDG-PET–Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders Superhuman Performance of a Large Language Model on The Reasoning Tasks of a Physician A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial Disclosures can be found at Neurology.org. 

The December 2025 recall features four previously released episodes focused on neuropalliative care. The episode begins with Dr. Stacey Clardy speaking with Dr. Janis Miyasaki about her path into neurology, the integration of palliative care into neurologic practice, and the essential role of patient-centered care. The conversation continues with Dr. Miranda Wan addressing strategies to enhance training and public awareness to optimize palliative care for patients with neurologic conditions. The recall concludes with Dr. Carolyn Rennels discussing the characteristics and motivations of patients with ALS who sought medical aid in dying in a two-part series.  Podcast links: 2025 AAN President's Award Recipient - Dr. Janis Miyasaki  Attitudes and Perceptions on Palliative Care Characteristics and Motivations of People With ALS Who Pursue Medical Aid in Dying - Part 1 Characteristics and Motivations of People With ALS Who Pursue Medical Aid in Dying - Part 2 Article links: 2025 AAN President's Award Neurologists' Attitudes and Perceptions on Palliative Care: A Qualitative Study  Characteristics and Motivations of People With Amyotrophic Lateral Sclerosis Who Pursue Medical Aid in Dying in California Disclosures can be found at Neurology.org.   

In a special episode of the Neurology Podcast, Dr. Stacey Clardy discusses how AI is shaping various aspects of our lives, including podcasts.  Read the related article in Neurology® Open Access.  Disclosures can be found at Neurology.org.  

In part two of this series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss gender disparities in the treatment of multiple sclerosis.  Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated.  Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

Dr. Stacey Clardy talks with Dr. Sandra Vukusic about the disparities in treatment for female patients with multiple sclerosis, particularly focusing on how pregnancy influences treatment decisions and the overall lower exposure to disease-modifying therapies in women compared to men.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org.  

The November 2025 Recall revisits four insightful episodes centered on muscle and neuromuscular diseases. Kicking off the episode is a two-part series on myositis, where Dr. Stacey Clardy speaks with Dr. Andrew Mammen. The episode continues with an interview featuring Dr. Eric Voorn, who discusses the effectiveness of combining personalized, home-based aerobic exercise with coaching to improve physical fitness in individuals with neuromuscular diseases. The episode wraps up with Dr. Elia Sechi discussing the critical role of interpreting lab test results, understanding assay performance, and recognizing the real-world impact of false positives in myasthenia gravis diagnostics.  Podcast links: Updates on All Things Myositis – Part 1  Updates on  All Things Myositis - Part 2 Efficacy of Aerobic Exercise and Coaching on Physical Fitness in Neuromuscular Disease  False Positivity of Acetylcholine Receptor Autoantibodies in Clinical Practice Article links: Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice Show citations:  Oorschot S, Brehm MA, van Groenestijn AC, et al. Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases: A Randomized Clinical Trial. Neurology. 2025;105(1):e213781. doi:10.1212/WNL.0000000000213781 Zara P, Chessa P, Deiana GA, et al. Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice. Neurology. 2025;104(9):e213498. doi:10.1212/WNL.0000000000213498 Disclosures can be found at Neurology.org.   

In part two of this two-part series, Dr. Stacey Clardy and Dr. Walter Koroshetz discuss ways to empower professionals in the fields of neurology and research. 

In part two of this two-part series, Dr. Stacey Clardy talks with Dr. Walter Koroshetz about overcoming funding challenges, the importance of rigor and reputation, unmet needs in neurology, and leveraging AI in neurology research.  Disclosures can be found at Neurology.org.  

In the first part of this two-part series, Dr. Stacey Clardy and Dr. Walter Koroshetz discuss strategies for advancing the fields of neurology and neuroscience research. 

In part one of this two-part series, Dr. Stacey Clardy talks with Dr. Walter Koroshetz about recent advancements in neurology, emerging genomic therapies, the evolving understanding of long COVID, and current NINDS priorities. Disclosures can be found at Neurology.org. 

In part two of this two-part series, Dr. Stacey Clardy and Dr. Andrew Mammen discuss what's new in the diagnosis and treatment of dermatomyositis. 

In part two of this two-part series, Dr. Stacey Clardy talks with Dr. Andrew Mammen about treatment options, real-world case studies, and future directions in myositis research.  Disclosures can be found at Neurology.org. 

In the first part of this two-part series, Dr. Stacey Clardy and Dr. Andrew Mammen discuss the advancements made over the past decade regarding HMGCR antibody-associated myositis and how to treat it. 

In part one of this two-part series, Dr. Stacey Clardy talks with Dr. Andrew Mammen about the different types of myositis, approaches to diagnosis, available diagnostic tools, and the evolving roles of MRI and biopsy in clinical practice.  Disclosures can be found at Neurology.org. 

In part two of this two-part series, Dr. Stacey Clardy and Casey R. Vanderlip discuss the changes that neurologists should implement in their clinics based on the findings from this study regarding APOE genotype.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213853  

In part one of this two part series, Dr. Stacey Clardy and Casey R. Vanderlip discuss what neurologists need to know about how APOE4 and amyloid interact to impact cognitive function.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213853 

Dr. Stacey Clardy talks with Casey R. Vanderlip about whether the accelerated decline in episodic memory among APOE4 carriers is due to increased Aβ deposition or heightened susceptibility to Aβ-related effects.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

In part two of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss how to approach the management of patients in clinic when there is concern for a possible false positive on the radioimmunoprecipitation assay for the acetylcholine receptor antibody. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss the clinical scenarios where the commonly used assay for myasthenia gravis is most likely to produce false positive results in patients who do not actually have myasthenia gravis. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498  

Dr. Stacey Clardy talks with Dr. Elia Sechi about the importance of understanding lab test results, the performance characteristics of assays, and the real-world implications of false positives in myasthenia gravis testing. Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

In the second installment of this two-part series, Dr. Stacey Clardy and Dr. Janis Miyasaki discuss how she got involved with the AAN.  Show reference:  https://www.aan.com/news/aan-honors-leader-volunteer-2025-presidents-award  

In the first installment of this two-part series, Dr. Stacey Clardy engages in a thought-provoking conversation with Dr. Janis Miyasaki, asking her to share two invaluable pieces of wisdom. Show reference:  https://www.aan.com/news/aan-honors-leader-volunteer-2025-presidents-award 

Dr. Stacey Clardy talks with Dr. Janis Miyasaki about her journey into neurology, the integration of palliative care into neurologic practice, and the critical importance of patient-centered care. Read more about the 2025 AAN President's Award.  Disclosures can be found at Neurology.org. 

Dr. Stacey Clardy breaks down the understanding of antiphospholipid syndrome.  Show references: https://ard.eular.org/article/S0003-4967(24)10290-7/fulltext 

In this lab minute, Dr. Stacey Clardy talks about paraneoplastic panels. 

Dr. Stacey Clardy discusses when to test for myasthenia gravis in this lab minute. 

Dr. Stacey Clardy discusses the fundamentals of the immune response to infection and explains how to accurately distinguish between past and current or recent infections.

Ring in the new year with the January 2025 replay of previously released episodes discussing the rise of science sleuths. In this three-part series Dr. Stacey Clardy talks with Dr. Elisabeth Bik and Dr. Matthew Schrag about critical issues surrounding research integrity and misconduct. Podcast Links: The Rise of the Science Sleuths - Part 1 The Rise of the Science Sleuths - Part 2 The Rise of the Science Sleuths - Part 3  Article Link: The Rise of the Science Sleuths  Disclosures can be found at Neurology.org.

In this episode of Neurology Minute, Dr. Stacey Clardy discusses Amyloidosis. Show reference: https://doi.org/10.1111/imj.15974     

In the second part of this two-part series, Dr. Stacey Clardy and Dr. Bhooma R. Aravamuthan talk about the future of the diagnostic label for cerebral palsy. Show reference: https://www.neurology.org/doi/10.1212/CPJ.0000000000200353  

In the first part of this two-part series, Dr. Stacey Clardy and Dr. Bhooma R. Aravamuthan discuss the current definition of cerebral palsy and the appropriate diagnostic labeling in clinical practice. Show reference: https://www.neurology.org/doi/10.1212/CPJ.0000000000200353 

Dr. Stacey Clardy talks with Dr. Bhooma Aravamuthan about the modern definition of cerebral palsy, the philosophical implications of diagnostic labels, and the need for clarity in clinical practice. Read the related article in Neurology: Clinical Practice.  Disclosures can be found at Neurology.org.

In the second episode of this two-part series, Dr. Stacey Clardy and Dr. Catherine Albin discuss the differences between traditional educational methods and the innovative use of social media for teaching. Show references: https://www.neurology.org/doi/10.1212/NE9.0000000000200160  

In the first episode of this two-part series, Dr. Stacey Clardy and Dr, Catherine Albin discuss the key features of educational social media posts that drive high sharing and engagement. Show references: https://www.neurology.org/doi/10.1212/NE9.0000000000200160 

Dr. Stacey Clardy talks with Dr. Catherine Albin about the key features of educational social media posts, strategies for creating impactful content, the importance of visual appeal, and the role of community engagement in neurology education. Read the related article in Neurology: Education.  Disclosures can be found at Neurology.org.

In part two of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss abandoning the term lupus myelitis and emphasize the importance of accurately naming and identifying each autoimmune condition. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329  

In part one of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss key features of inflammatory myelopathy in rheumatologic disease, helping to better characterize the underlying causes of lupus myelitis. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329 

Dr. Stacey Clardy talks with Dr. Elias Sotirchos about the underlying etiologies of myelitis in patients with rheumatologic disease. Read the related article in Neurology: Neuroimmunology & Neuroinflammation. Disclosures can be found at Neurology.org.